Displaying 661 - 680 of 853
| Active Ingredient | OESTRADIOL |
| Therapeutic Class | ESTROGENS |
| Indications | HRT (may be cyclical and progestogen should be added for 10-14 days of the cycle or may be continuously combined). Prevention of post-menopausal osteoporosis and vascular disease. Atrophic va More ... |
| Caution | Less thromboembolic disease than semisyntheticor synthetic oestrogen, spotting, breast tenderness, chloasma, weight changes. C.f. prescribing in liver disease p. 16. |
| Dose Range |
Oral: 0.5-2mg daily . Vaginal: 2-4g (0.2-0.4mg oestradiol) daily for 1-2 weeks, then increase to 1-2g/day for 1-2 weeks; then maintainance dose of 1g 1-3 times weekly for 3 weeks, then off for 1 week; then rep eat cy cle once vaginal muco |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTROGENS CONJUGATED |
| Therapeutic Class | ESTROGENS |
| Indications |
Prevention of post-menopausal osteoporosis.Atrophic vaginitis; atrophic urethritis, estrogen replacement.HRT (may be cyclical and progestogen should be added for 10-14 days of the cy le or may be More ... |
| Caution |
Headache, nausea, hypertension, vaginal bleeding, weight changes. c.f. prescribing in liver disease p. 16. |
| Dose Range | Oral: 0.3-1.25mg daily .; i.v/i.m: 25mg may repeat in 6-12 hours if necessary; vaginal cream: 2-4g daily for 3 weeks, off for 1 week then repeat . Breast Cancer: 10 mg three times daily for at least 3 months. Prostate Cancer: 1.25 - 2.5mg 3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CLOMIPHENE |
| Therapeutic Class | ESTROGEN AGONIST-ANTAGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RALOXIFENE |
| Therapeutic Class | ESTROGEN AGONIST-ANTAGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRADIOL | DROSPIRENONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRADIOL | NORETHISTERONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTRADIOL | CYPROTERONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTRADIOL | NORGESTREL |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HUMAN CHORIONIC GONADOTROPHIN |
| Therapeutic Class | GONADATROPINS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIDIABETIC AGENTS |
| Therapeutic Class | ANTIDIABETIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ACARBOSE |
| Therapeutic Class | ALPHA GLUCOSIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN |
| Therapeutic Class | BIGUANIDES |
| Indications |
Diabetes mellitus in obese, mature onset, diabetes without ketosis, when diet and attempts at weight loss fail. |
| Caution |
Anorexia or dyspep sia occurs in 15% of cases. Lactic acidosis is an infrequent side effect. Nausea, vomiting, diarrhoea, flatulence. C.f. Prescribing in liver and renal disease p. 15; 32. Not recom More ... |
| Dose Range |
500mg 2-3 times daily or 850mg once or twice daily with or after meals. Gradually increase at intervals of at least 1 week, to 2- 3 g daily . Doses greater than 2g, give in 3 divided doses. Extended Release: Initial dose of 500 mg once daily in |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR |
| Therapeutic Class | BIGUANIDES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LINAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN XR | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SAXAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | METFORMIN | VILDAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SITAGLIPTIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SITAGLIPTIN | METFORMIN |
| Therapeutic Class | DIPEPTIDYL PEPTIDASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |